These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

826 related articles for article (PubMed ID: 27338953)

  • 1. Structural basis of potent Zika-dengue virus antibody cross-neutralization.
    Barba-Spaeth G; Dejnirattisai W; Rouvinski A; Vaney MC; Medits I; Sharma A; Simon-Lorière E; Sakuntabhai A; Cao-Lormeau VM; Haouz A; England P; Stiasny K; Mongkolsapaya J; Heinz FX; Screaton GR; Rey FA
    Nature; 2016 Aug; 536(7614):48-53. PubMed ID: 27338953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus.
    Swanstrom JA; Plante JA; Plante KS; Young EF; McGowan E; Gallichotte EN; Widman DG; Heise MT; de Silva AM; Baric RS
    mBio; 2016 Jul; 7(4):. PubMed ID: 27435464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models.
    Shukla R; Beesetti H; Brown JA; Ahuja R; Ramasamy V; Shanmugam RK; Poddar A; Batra G; Krammer F; Lim JK; Kale S; Lal AA; Swaminathan S; Khanna N
    EBioMedicine; 2020 Oct; 60():102991. PubMed ID: 32949997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dengue and Zika Virus Domain III-Flagellin Fusion and Glycan-Masking E Antigen for Prime-Boost Immunization.
    Lin HH; Yang SP; Tsai MJ; Lin GC; Wu HC; Wu SC
    Theranostics; 2019; 9(16):4811-4826. PubMed ID: 31367259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural Basis of Zika Virus Specific Neutralization in Subsequent Flavivirus Infections.
    Sevvana M; Rogers TF; Miller AS; Long F; Klose T; Beutler N; Lai YC; Parren M; Walker LM; Buda G; Burton DR; Rossmann MG; Kuhn RJ
    Viruses; 2020 Nov; 12(12):. PubMed ID: 33255202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
    Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of differential Zika and dengue virus neutralization by a public antibody lineage targeting the DIII lateral ridge.
    Zhao H; Xu L; Bombardi R; Nargi R; Deng Z; Errico JM; Nelson CA; Dowd KA; Pierson TC; Crowe JE; Diamond MS; Fremont DH
    J Exp Med; 2020 Feb; 217(2):. PubMed ID: 31757867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-reactive dengue virus-derived monoclonal antibodies to Zika virus envelope protein: Panacea or Pandora's box?
    Gunawardana SA; Shaw RH
    BMC Infect Dis; 2018 Dec; 18(1):641. PubMed ID: 30526531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis for Zika envelope domain III recognition by a germline version of a recurrent neutralizing antibody.
    Esswein SR; Gristick HB; Jurado A; Peace A; Keeffe JR; Lee YE; Voll AV; Saeed M; Nussenzweig MC; Rice CM; Robbiani DF; MacDonald MR; Bjorkman PJ
    Proc Natl Acad Sci U S A; 2020 May; 117(18):9865-9875. PubMed ID: 32321830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The epitope arrangement on flavivirus particles contributes to Mab C10's extraordinary neutralization breadth across Zika and dengue viruses.
    Sharma A; Zhang X; Dejnirattisai W; Dai X; Gong D; Wongwiwat W; Duquerroy S; Rouvinski A; Vaney MC; Guardado-Calvo P; Haouz A; England P; Sun R; Zhou ZH; Mongkolsapaya J; Screaton GR; Rey FA
    Cell; 2021 Dec; 184(25):6052-6066.e18. PubMed ID: 34852239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T Cell Responses Induced by Attenuated Flavivirus Vaccination Are Specific and Show Limited Cross-Reactivity with Other Flavivirus Species.
    Grifoni A; Voic H; Dhanda SK; Kidd CK; Brien JD; Buus S; Stryhn A; Durbin AP; Whitehead S; Diehl SA; De Silva AD; Balmaseda A; Harris E; Weiskopf D; Sette A
    J Virol; 2020 May; 94(10):. PubMed ID: 32132233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and purification of domain III proteins from Dengue and Zika viruses.
    Corzo-Gómez J; García-Cordero J; Montes Gómez AE; Bernal-Siria K; Namorado-Tónix K; Gutierrez-Castañeda B; Cedillo-Barrón L
    Protein Expr Purif; 2019 Oct; 162():38-43. PubMed ID: 31112759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zika Virus Envelope Protein and Antibody Complexes.
    Dai L; Wang Q; Song H; Gao GF
    Subcell Biochem; 2018; 88():147-168. PubMed ID: 29900496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Landscape of Monoclonal Antibodies Targeting Zika and Dengue: Therapeutic Solutions and Critical Insights for Vaccine Development.
    Dussupt V; Modjarrad K; Krebs SJ
    Front Immunol; 2020; 11():621043. PubMed ID: 33664734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity.
    Lai H; Paul AM; Sun H; He J; Yang M; Bai F; Chen Q
    Vaccine; 2018 Mar; 36(14):1846-1852. PubMed ID: 29490880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational Engineering and Characterization of an mAb that Neutralizes Zika Virus by Targeting a Mutationally Constrained Quaternary Epitope.
    Tharakaraman K; Watanabe S; Chan KR; Huan J; Subramanian V; Chionh YH; Raguram A; Quinlan D; McBee M; Ong EZ; Gan ES; Tan HC; Tyagi A; Bhushan S; Lescar J; Vasudevan SG; Ooi EE; Sasisekharan R
    Cell Host Microbe; 2018 May; 23(5):618-627.e6. PubMed ID: 29746833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zika Virus-Like Particles Bearing a Covalent Dimer of Envelope Protein Protect Mice from Lethal Challenge.
    De Lorenzo G; Tandavanitj R; Doig J; Setthapramote C; Poggianella M; Sanchez-Velazquez R; Scales HE; Edgar JM; Kohl A; Brewer J; Burrone OR; Patel AH
    J Virol; 2020 Dec; 95(1):. PubMed ID: 33028720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor.
    Dussupt V; Sankhala RS; Gromowski GD; Donofrio G; De La Barrera RA; Larocca RA; Zaky W; Mendez-Rivera L; Choe M; Davidson E; McCracken MK; Brien JD; Abbink P; Bai H; Bryan AL; Bias CH; Berry IM; Botero N; Cook T; Doria-Rose NA; Escuer AGI; Frimpong JA; Geretz A; Hernandez M; Hollidge BS; Jian N; Kabra K; Leggat DJ; Liu J; Pinto AK; Rutvisuttinunt W; Setliff I; Tran U; Townsley S; Doranz BJ; Rolland M; McDermott AB; Georgiev IS; Thomas R; Robb ML; Eckels KH; Barranco E; Koren M; Smith DR; Jarman RG; George SL; Stephenson KE; Barouch DH; Modjarrad K; Michael NL; Joyce MG; Krebs SJ
    Nat Med; 2020 Feb; 26(2):228-235. PubMed ID: 32015557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design.
    Li XQ; Qiu LW; Chen Y; Wen K; Cai JP; Chen J; Pan YX; Li J; Hu DM; Huang YF; Liu LD; Ding XX; Guo YH; Che XY
    J Gen Virol; 2013 Oct; 94(Pt 10):2191-2201. PubMed ID: 23851440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-Reactive T Cell Immunity to Dengue and Zika Viruses: New Insights Into Vaccine Development.
    Elong Ngono A; Shresta S
    Front Immunol; 2019; 10():1316. PubMed ID: 31244855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.